• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by HOOKIPA Pharma Inc.

    2/14/25 4:25:29 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOOK alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)


    HOOKIPA Pharma Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    43906K209

    (CUSIP Number)


    Armance Bordes
    7-11, boulevard Haussmann,
    Paris, I0, 75009
    33 1 76 23 41 09


    John Partigan Lloyd Spencer
    Nixon Peabody LLP, 799 9 Street NW Ste 500
    Washington, DC, 20001
    202-585-8000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    02/14/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    43906K209


    1 Name of reporting person

    Sofinnova Capital VI FCPR
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    FRANCE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    314,259.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    314,259.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    314,259.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.6 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    Note in relation to Items 7 and 8: Sofinnova Partners SAS, a French corporation ("SP SAS"), the management company of Sofinnova Capital VI FCPR ("SC VI"), may be deemed to have sole voting power, and Antoine Papiernik ("Papiernik"), Henrijette Richter ("Richter"), Maina Bhaman ("Bhaman"), Graziano Seghezzi ("Seghezzi"), Anta Gkelou ("Gkelou") and Karl Naegler ("Naegler"), the members of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note in relation to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Papiernik, Richter, Bhaman, Seghezzi, Gkelou and Naegler, the members of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 9,655,022 shares of common stock and 2,399,517 shares of Class A common stock outstanding as of November 11, 2024, as reported in HOOKIPA's Form 10-Q filed with the SEC on November 14, 2024.


    SCHEDULE 13D

    CUSIP No.
    43906K209


    1 Name of reporting person

    Sofinnova Partners SAS
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    FRANCE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    314,259.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    314,259.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    314,259.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.6 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    Note in relation to Items 7 and 8: SP SAS, the management company of SC VI, may be deemed to have sole voting power, and Papiernik, Richter, Bhaman, Seghezzi, Gkelou and Naegler, the members of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note in relation to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Papiernik, Richter, Bhaman, Seghezzi, Gkelou and Naegler, the members of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 9,655,022 shares of common stock and 2,399,517 shares of Class A common stock outstanding as of November 11, 2024, as reported in HOOKIPA's Form 10-Q filed with the SEC on November 14, 2024.


    SCHEDULE 13D

    CUSIP No.
    43906K209


    1 Name of reporting person

    Antoine Papiernik
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    FRANCE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    314,259.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    314,259.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    314,259.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.6 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Note to Items 7 and 8: SP SAS, the management company of SC VI, may be deemed to have sole voting power, and Papiernik, a member of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Papiernik, a member of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 9,655,022 shares of common stock and 2,399,517 shares of Class A common stock outstanding as of November 11, 2024, as reported in HOOKIPA's Form 10-Q filed with the SEC on November 14, 2024.


    SCHEDULE 13D

    CUSIP No.
    43906K209


    1 Name of reporting person

    Henrijette Richter
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DENMARK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    314,259.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    314,259.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    314,259.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.6 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Note to Items 7 and 8: SP SAS, the management company of SC VI, may be deemed to have sole voting power, and Richter, a member of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Richter, a member of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 9,655,022 shares of common stock and 2,399,517 shares of Class A common stock outstanding as of November 11, 2024, as reported in HOOKIPA's Form 10-Q filed with the SEC on November 14, 2024.


    SCHEDULE 13D

    CUSIP No.
    43906K209


    1 Name of reporting person

    Maina Bhaman
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    314,259.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    314,259.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    314,259.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.6 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Note to Items 7 and 8: SP SAS, the management company of SC VI, may be deemed to have sole voting power, and Bhaman, a member of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Bhaman, a member of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 9,655,022 shares of common stock and 2,399,517 shares of Class A common stock outstanding as of November 11, 2024, as reported in HOOKIPA's Form 10-Q filed with the SEC on November 14, 2024.


    SCHEDULE 13D

    CUSIP No.
    43906K209


    1 Name of reporting person

    Graziano Seghezzi
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    ITALY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    314,259.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    314,259.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    314,259.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.6 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Note to Items 7 and 8: SP SAS, the management company of SC VI, may be deemed to have sole voting power, and Seghezzi, a member of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Seghezzi, a member of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 9,655,022 shares of common stock and 2,399,517 shares of Class A common stock outstanding as of November 11, 2024, as reported in HOOKIPA's Form 10-Q filed with the SEC on November 14, 2024.


    SCHEDULE 13D

    CUSIP No.
    43906K209


    1 Name of reporting person

    Anta Gkelou
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    GREECE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    314,259.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    314,259.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    314,259.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.6 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Note to Items 7 and 8: SP SAS, the management company of SC VI, may be deemed to have sole voting power, and Gkelou, a member of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Gkelou, a member of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 9,655,022 shares of common stock and 2,399,517 shares of Class A common stock outstanding as of November 11, 2024, as reported in HOOKIPA's Form 10-Q filed with the SEC on November 14, 2024.


    SCHEDULE 13D

    CUSIP No.
    43906K209


    1 Name of reporting person

    Karl Naegler
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    GERMANY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    314,259.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    314,259.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    314,259.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    2.6 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Note to Items 7 and 8: SP SAS, the management company of SC VI, may be deemed to have sole voting power, and Naegler, a member of the investment committee of SC VI, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC VI, may be deemed to have sole power to dispose of these shares, and Naegler, a member of the investment committee of SC VI, may be deemed to have shared power to dispose of these shares. Note in relation to Items 13: Percentage of class is calculated based on 9,655,022 shares of common stock and 2,399,517 shares of Class A common stock outstanding as of November 11, 2024, as reported in HOOKIPA's Form 10-Q filed with the SEC on November 14, 2024.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.0001 per share
    (b)Name of Issuer:

    HOOKIPA Pharma Inc.
    (c)Address of Issuer's Principal Executive Offices:

    350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NEW YORK , 10118.
    Item 1 Comment:
    Introductory Statement: This Amendment No. 5 (this "Amendment"), being filed by Sofinnova Capital VI FCPR ("SC VI"), Sofinnova Partners SAS, a French corporation ("SP SAS"), Antoine Papiernik ("Papiernik"), Henrijette Richter ("Richter"), Maina Bhaman ("Bhaman"), Graziano Seghezzi ("Seghezzi"), Anta Gkelou and Karl Naegler the members of the investment committee of SC VI (collectively, the "Listed Persons" and together with SC VI and SP SAS, the "Reporting Persons"), amends and supplements (i) the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on April 30, 2019, (ii) the Amendment No. 1 to the Schedule 13D filed with the SEC on February 2, 2021, (iii) the Amendment No. 2 to the Schedule 13D filed with the SEC on March 31, 2021, (iv) the Amendment No. 3 to the Schedule 13D filed with the SEC on April 22, 2021, and (v) the Amendment No. 4 to the Schedule 13D filed with the SEC on February 13, 2023 (collectively, the "Schedule 13D"). This Schedule 13D relates to the shares of common stock (the "Common Stock") of HOOKIPA Pharma Inc., a Delaware corporation (the "Issuer"). Except as specifically provided herein, this Amendment No. 5 does not modify any of the information previously reported in the Schedule 13D, as amended. Capitalized terms used herein shall have the meanings ascribed to them in the Schedule 13D.
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: This Amendment is being filed to reflect a decrease in the Reporting Persons' percentage ownership of the Issuer's Common Stock, which resulted from an increase in the number of shares outstanding since the filing of Amendment No. 4 to Schedule 13D and is not due to any transactions in the shares of Common Stock by the Reporting Persons. Percentage of class is calculated based on 9,655,022 shares of common stock and 2,399,517 shares of Class A common stock outstanding as of November 11, 2024, as reported in HOOKIPA's Form 10-Q filed with the SEC on November 14, 2024.
    (b)
    Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows: See the information contained on the cover pages of this Amendment, which is incorporated herein by reference.
    (c)
    Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: There have been no reportable transactions with respect to the shares of Common Stock of the Issuer within the last 60 days by the Reporting Persons.
    (e)
    The amount of outstanding shares of Common Stock was substantially increased in June 2023 when the Issuer closed a public offering of Common Stock.
    Item 7.Material to be Filed as Exhibits.
     
    EX 99.1 - Joint Filing Agreement, dated as of February 14, 2025, by and among Sofinnova Capital VI FCPR, Sofinnova Partners SAS, Antoine Papiernik, Henrijette Richter, Maina Bhaman, Graziano Seghezzi, Anta Gkelou and Karl Naegler

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Sofinnova Capital VI FCPR
     
    Signature:/s/ Antoine Papiernik
    Name/Title:Antoine Papiernik / Managing Partner
    Date:02/14/2025
     
    Sofinnova Partners SAS
     
    Signature:/s/ Antoine Papiernik
    Name/Title:Antoine Papiernik / Managing Partner
    Date:02/14/2025
     
    Antoine Papiernik
     
    Signature:/s/ Antoine Papiernik
    Name/Title:Antoine Papiernik
    Date:02/14/2025
     
    Henrijette Richter
     
    Signature:/s/ Henrijette Richter
    Name/Title:Henrijette Richter
    Date:02/14/2025
     
    Maina Bhaman
     
    Signature:/s/ Maina Bhaman
    Name/Title:Maina Bhaman
    Date:02/14/2025
     
    Graziano Seghezzi
     
    Signature:/s/ Graziano Seghezzi
    Name/Title:Graziano Seghezzi
    Date:02/14/2025
     
    Anta Gkelou
     
    Signature:/s/ Anta Gkelou
    Name/Title:Anta Gkelou
    Date:02/14/2025
     
    Karl Naegler
     
    Signature:/s/ Karl Naegler
    Name/Title:Karl Naegler
    Date:02/14/2025
    Get the next $HOOK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HOOK

    DatePrice TargetRatingAnalyst
    12/20/2024$48.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    11/15/2024$50.00 → $48.00Outperform
    RBC Capital Mkts
    12/2/2022Neutral → Underperform
    BofA Securities
    2/17/2022$15.00 → $8.00Buy
    HC Wainwright & Co.
    2/16/2022$3.00 → $4.00Outperform
    SVB Leerink
    11/12/2021$6.00Overweight → Equal-Weight
    Morgan Stanley
    11/11/2021$21.00 → $15.00Buy
    HC Wainwright & Co.
    11/10/2021$28.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $HOOK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV

      HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV) Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial Primary completion expected H2 2025 NEW YORK and VIENNA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that enrollment is complete in th

      1/30/25 7:00:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

      NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, today announced a notice to shareholders regarding U.K. disclosure requirements. HOOKIPA directs the attention of its shareholders to certain disclosure requirements applicable to the potential all-share acquisition by HOOKIPA of Poolbeg Pharma plc, which was announced on January 2, 2025. HOOKIPA's shares are admitted to trading on the NASDAQ Capital Market exchange. The relevant disclosure requirements are set out in

      1/7/25 4:05:00 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

      Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset presented at recent RAS Targeted Drug Development Summit NEW YORK and VIENNA, Austria, Nov. 14, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")

      11/14/24 4:05:00 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOOK
    SEC Filings

    See more
    • Amendment: SEC Form 10-K/A filed by HOOKIPA Pharma Inc.

      10-K/A - HOOKIPA Pharma Inc. (0001760542) (Filer)

      4/30/25 5:03:22 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)

      2/20/25 4:01:17 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by HOOKIPA Pharma Inc.

      SCHEDULE 13D/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

      2/14/25 4:25:29 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HOOKIPA Pharma downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded HOOKIPA Pharma from Outperform to Sector Perform and set a new price target of $2.00 from $48.00 previously

      12/20/24 7:37:05 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target

      RBC Capital Mkts reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $48.00 from $50.00 previously

      11/15/24 11:07:50 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma downgraded by BofA Securities

      BofA Securities downgraded HOOKIPA Pharma from Neutral to Underperform

      12/2/22 12:03:07 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP and CFO Coelho Mary Theresa was granted 69,875 shares (SEC Form 4)

      4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

      7/24/24 4:18:15 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Peters Malte was granted 108,695 shares (SEC Form 4)

      4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

      7/24/24 4:17:16 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cassidy Sean A

      4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

      7/24/24 4:16:22 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOOK
    Leadership Updates

    Live Leadership Updates

    See more
    • HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

      Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset presented at recent RAS Targeted Drug Development Summit NEW YORK and VIENNA, Austria, Nov. 14, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")

      11/14/24 4:05:00 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Announces Board of Directors Changes

      NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O'Neill as Non-Executive Chair of the Company's Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his o

      8/30/24 8:00:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

      New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 "AVALON-1" study with eseba-vec in Q4 2024 ASCO 2024 Presentation:   Reported best-in-class Phase 2 data for first-line HPV16+ head and neck cancer patients treated with eseba-vec (formerly HB-200) in combination with pembrolizumab during oral presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingRegulatory Progress:   Announced alignment with U.S. Food and Drug Administration (FDA) for the AVALON-1 Phase 2/3 pivotal trial design and protocol for eseba-vec, in combination with pembrolizumab for the first-li

      8/8/24 4:30:00 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

      SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

      11/14/24 6:07:08 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

      SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

      8/2/24 6:38:55 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by HOOKIPA Pharma Inc.

      SC 13G - HOOKIPA Pharma Inc. (0001760542) (Subject)

      7/8/24 6:51:26 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOOK
    Financials

    Live finance-specific insights

    See more
    • HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

      Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of careCompany will host a conference call at 4:15 p.m. ET today NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) -- H

      6/4/24 1:00:44 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

      Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:00 a.m. ET on Thursday, April 25, 2024, to highlight path to potential registration; participant details below NEW YORK and VIENNA, Austria, April 25, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDA

      4/25/24 7:01:00 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

      NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its third quarter 2023 financial results and business highlights on November 9, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight o

      11/2/23 4:01:00 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care